Sacubitril/Valsartan and Heart Failure: Improvement of Health Status

Sacubitril/Valsartan and Heart Failure: Improvement of Health Status Posted By:
...

For the last few years, we have seen a number of continuing education sessions and articles related to advances in the treatment of heart failure (HF). One of the newer medications, sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been added as a preferred agent for treatment of HF with reduced ejection fraction (HFrEF) in the 2021 Update to the American College of Cardiology (ACC) consensus algorithm.

A recent article in JACC Heart Failure highlighted promising news about improvement in health status for patients who initiated on sacubitril/valsartan. The study, which took place over 12 months, evaluated changes from baseline in both Kansas City Cardiomyopathy Questionnaire (KCCQ)-23 responses and amino-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. The results showed that patients who were started on sacubitril/valsartan had a rapid improvement in KCCQ-23 scores that was significantly related to changes in their NT-proBNP levels.

This is promising news for our patients with HFrEF. Using sacubitril/valsartan appropriately in HFrEF can help patients feel better earlier—consequently allowing for greater quality of life and increasing the odds that they will adhere to the treatment regimen.

References
  • Maddox TM, et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction: A report of the American College of Cardiology Solution Set Oversight Committee. JACC. 2021;77:772.
  • Pina IL, et al. Improvement of health status following initiation of sacubitril/valsartan in heart failure and reduced ejection fraction. JACC Heart Fail. 2021;9:42.

Share

Filed under: Cardiometabolic

Related
Atrial Fibrillation: Optimizing Outcomes by Addressing Social Determinants of Health and Implicit Bias

Atrial Fibrillation: Optimizing Outcomes by Addres ...

Atrial fibrillation (AF) is the most common sustained arrhythmia diagnosed, and its prevalence is ex ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
My Experience With GLP-1 Receptor Agonists in Patients With Type 2 Diabetes

My Experience With GLP-1 Receptor Agonists in Pati ...

When considering the benefits of glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) for our pat ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
Dietary Sodium Restriction in Patients With Heart Failure

Dietary Sodium Restriction in Patients With Heart ...

There are about 6.2 million adults in the United States living with heart failure (HF), according to ...

Filed under: Cardiometabolic, Pulmonary Medicine


Continue Reading
Bleeding Risk with Apixaban and Systemic Fluconazole Use

Bleeding Risk with Apixaban and Systemic Fluconazo ...

We, as healthcare professionals, are aware that we must check for drug interactions in our patients ...

Filed under: Cardiometabolic, Pulmonary Medicine


Continue Reading
Cardiovascular Risk in Rheumatic Inflammatory Disease

Cardiovascular Risk in Rheumatic Inflammatory Dise ...

It is well documented that those with rheumatic inflammatory diseases have an increased risk of card ...

Filed under: Cardiometabolic, Rheumatology


Continue Reading
The Latest on Heart Failure: Clinical Trials Summary

The Latest on Heart Failure: Clinical Trials Summa ...

Too often, we are faced with hectic workdays that lead into hectic home lives—when we clock ou ...

Filed under: Cardiometabolic


Continue Reading